194 completed, 17 unknown, 13 terminated, 3 withdrawn. 227 Phase 2, 26 Phase 1, 19 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 227 | Completed 194, Unknown 17, Terminated 13, Withdrawn 3 |
| Phase 1 | 26 | Completed 20, Terminated 4, Unknown 1, Withdrawn 1 |
| Phase 3 | 19 | Completed 13, Unknown 4, Terminated 1, Withdrawn 1 |
Follow Hepatitis C, Chronic: new trials by email Literature Review of Hepatitis C, Chronic trials Research Report on Hepatitis C, Chronic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Bemnifosbuvir, Ruzasvir - Chronic Hepatitis C Virus, Hepatitis C, Chronic | Phase 2 | Completed | Atea Pharmaceuticals, Inc. | 275 | 2023-05-30 | 2025-10-21 |
| Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects AT-777, Placebo, AT-527 - Hepatitis C, Hepatitis C, Chronic | Phase 1 / Phase 2 | Withdrawn | Atea Pharmaceuticals, Inc. | 2021-10-01 | 2022-06-08 | |
| The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects HEC110114 Tablet, Sofosbuvir Tablet - Chronic Hepatitis C | Phase 1 / Phase 2 | Completed | Sunshine Lake Pharma Co., Ltd. | 24 | 2020-07-06 | 2020-09-10 |
| Prolonged Release Pirfenidone for Advanced Residual Liver Fibrosis (MINERVA). Prolonged-Release Pirfenidone - Liver Cirrhosis, Hepatitis C, Chronic | Phase 2 | Unknown | University of Guadalajara | 60 | 2019-08-01 | 2023-07-06 |
| Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection AT-527, Daclatasvir - Hepatitis C, Hepatitis C, Chronic | Phase 2 | Completed | Atea Pharmaceuticals, Inc. | 10 | 2019-06-20 | 2020-05-04 |
| SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C SH229 tablets, Daclatasvir dihydrochloride - Hepatitis C, Chronic | Phase 2 / Phase 3 | Unknown | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 440 | 2019-03-29 | 2019-08-28 |
| Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy Ledipasvir / Sofosbuvir Oral Product - Hepatitis C, Chronic, Hematologic Malignancy | Phase 1 / Phase 2 | Completed | Ain Shams University | 24 | 2019-03-01 | 2023-08-22 |
| Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL) CDI-31244, SOF/VEL - Chronic Hepatitis C | Phase 2 | Completed | Cocrystal Pharma, Inc. | 12 | 2018-06-26 | 2021-04-28 |
| Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C 20mg ezetimibe, Placebo, 40mg ezetimibe - Chronic Hepatitis C | Phase 2 | Terminated | VA Office of Research and Development | 2 | 2018-04-16 | 2022-06-06 |
| Treatment of Chronic Hepatitis C Infection by Ledipasvir/Sofosbuvir in Naïve Children Ledipasvir-Sofosbuvir 90 Mg-400 Mg Oral Tablet - Hepatitis C, Chronic | Phase 2 | Completed | Mansoura University Children Hospital | 50 | 2018-03-01 | 2021-10-25 |
| Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C] Sofosbuvir, Daclatasvir, Pegylated Interferon alfa-2a - Hepatitis C, Chronic | Phase 2 / Phase 3 | Completed | Johns Hopkins Bloomberg School of Public Health | 150 | 2018-02-02 | 2021-05-18 |
| Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination Simvastatin 10mg, sofosbuvir plus daclatasvir - Chronic Hepatitis c, Metabolic Syndrome | Phase 2 / Phase 3 | Completed | Ain Shams University | 100 | 2017-12-01 | 2018-09-20 |
| Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease SOF/VEL - Chronic Hepatitis C | Phase 2 | Completed | Gilead Sciences | 59 | 2017-03-22 | 2020-03-06 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation - Hepatitis C Virus (HCV) | Phase 2 / Phase 3 | Completed | AbbVie | 129 | 2017-03-20 | 2023-05-09 |
| Safety and Efficacy of KW-136 and Sofosbuvir for Treatment of Chronic Hepatitis C KW-136, Sofosbuvir - Hepatitis C, Chronic | Phase 2 | Completed | Kawin Technology Share-holding Co., Ltd. | 110 | 2017-02-15 | 2018-01-31 |
| A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive AL-335, Odalasvir (ODV), Simeprevir (SMV) - Hepatitis C, Chronic | Phase 2 | Completed | Janssen Pharmaceutical K.K. | 33 | 2016-12-21 | 2019-09-11 |
| Efficacy and Safety of Qurevo Plus Ribavirin Based Therapy for Hepatitis C With or Without Cirrhosis in Haemodialysis Patients Ombitasvir, Paritaprevir and Ritonavir - Chronic Hepatitis c | Phase 2 | Unknown | Ain Shams University | 40 | 2016-11-09 | 2018-01-18 |
| Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection AL-335, Odalasvir, Simeprevir - Hepatitis C, Chronic | Phase 2 | Completed | Janssen Research & Development, LLC | 365 | 2016-11-09 | 2019-11-20 |
| Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy LDV/SOF - Hepatitis C Virus Infection | Phase 2 | Completed | Gilead Sciences | 19 | 2016-08-28 | 2020-03-02 |
| Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035) Uprifosbuvir 450 mg, Ruzasvir 60 mg - Hepatitis C, Chronic | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 160 | 2016-05-03 | 2019-06-26 |
Showing 20 of 227. Sign in to see all of them.
Hepatitis C (85) · Hepatitis (12) · Liver Diseases (9) · Fibrosis (6) · Virus Diseases (6) · HIV Infections (5) · Liver Cirrhosis (4) · Bronchiolitis Obliterans Syndrome (3) · Hepatitis, Chronic (3) · Infections (3) · Acquired Immunodeficiency Syndrome (2) · Directly Observed Therapy (2) · Hepatitis, Viral, Human (2) · Insulin Resistance (2)
Blood-Borne Infections (227) · Chronic Disease (227) · Communicable Diseases (227) · Disease Attributes (227) · Pathologic Processes (227) · Pathological Conditions, Signs and Symptoms (227) · Digestive System Diseases (226) · Flaviviridae Infections (226) · RNA Virus Infections (226) · Hepatitis, Viral, Human (225) · Hepatitis, Chronic (224) · Infections (224) · Virus Diseases (221) · Liver Diseases (218) · Hepatitis (215)
Ribavirin (115) · peginterferon alfa-2a (59) · Sofosbuvir (20) · peginterferon alfa-2b (18) · Ritonavir (16) · daclatasvir (13) · Simeprevir (12) · ombitasvir (11) · telaprevir (11) · paritaprevir (10) · danoprevir (9) · ledipasvir (8) · nitazoxanide (8) · GS-9451 (7) · N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide (6)
Merck Sharp & Dohme LLC (23) · Gilead Sciences (16) · Hoffmann-La Roche (15) · AbbVie (12) · Bristol-Myers Squibb (8) · Boehringer Ingelheim (7) · Vertex Pharmaceuticals Incorporated (7) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (6) · Romark Laboratories L.C. (6) · AbbVie (prior sponsor, Abbott) (4) · BioWest Therapeutics Inc (4) · French National Agency for Research on AIDS and Viral Hepatitis (4) · GlaxoSmithKline (4) · ANRS, Emerging Infectious Diseases (3) · Ain Shams University (3)
United States (90) · France (35) · Germany (34) · Puerto Rico (31) · Canada (27) · Spain (22) · United Kingdom (20) · Australia (19) · New Zealand (16) · Belgium (15) · Poland (14) · Austria (13) · Egypt (13) · Taiwan (11) · Italy (9)
Asem Elfert, MD (4) · Jim Pankovich (4) · Armen Asatryan, MD (3) · Marc G Ghany, M.D. (3) · Yehia El-Gohary, MD (3)
PMID 30012435, PMID 30923816, PMID 30977945, PMID 24154738, PMID 24209977, PMID 26596948, PMID 28412293, PMID 31568620, PMID 15282352, PMID 15563253, PMID 15685543, PMID 15820563, PMID 15867490, PMID 16115185, PMID 16439867, PMID 18435468, PMID 18666223, PMID 18771667, PMID 19403902, PMID 19403903, PMID 19447518, PMID 20492507, PMID 20622678, PMID 20692693, PMID 20709593, PMID 20721883, PMID 20854821, PMID 21034680, PMID 21255610, PMID 21837752, PMID 22024518, PMID 22155914, PMID 22166557, PMID 22256805, PMID 22387529, PMID 22797645, PMID 22863266, PMID 22885330, PMID 23070151, PMID 23190183, PMID 23383655, PMID 23410147, PMID 23439259, PMID 23439365, PMID 23499440, PMID 23504694, PMID 23558093, PMID 23811112, PMID 23890273, PMID 23944300
2014 (6), 2009 (5), 2015 (4), 2004 (2), 2008 (2), 2016 (2), 2019 (2), R01DA026727 (2), 2005 (1)